Skip to main content

Table 1 Incidence of peripheral and axial disease

From: Early anti-inflammatory intervention ameliorates axial disease in the proteoglycan-induced spondylitis mouse model of ankylosing spondylitis

Treatment (treatment period) Vehicle (6.5–8) ETN + PRD (6.5–8) Vehicle (6.5–12) ETN + PRD (6.5–12)
Both peripheral and axial disease 80% 14.3% (p = 0.01) 100.0% 62.5% (p = 0.035)
Peripheral disease only 0 14.3% 0.0 25%
Axial disease only 20% 42.9% 0.0 12.5%
Presence of axial disease 100% 57.1% (p = 0.02) 100.0% 75% (p = 0.0015)
Incidence of peripheral disease 80% 28.6% 100% 87.5%
Peripheral disease incidence at treatment commencement 40% 28.6% 57.1% 62.5%
Total number 5 7 7 8
  1. The statistical significance of data was analysed by one-tailed Z-tests compared with vehicle at corresponding time points
  2. Abbreviations: ETN etanercept, PRD prednisolone